Quantitative mRNA Expression Assays and Synchronous Breast Cancers: A Case Report

In this report, a woman with synchronous primary breast cancers is described. Oncotype Dx testing was done on each of her two cancers. By assuming that the recurrence risk from each with adjuvant endocrine therapy is an independent event, the recurrence likelihood from one or the other or both is calculated. I propose that this calculated value more accurately should predict the recurrence from one or the other or both tumors with endocrine therapy or chemotherapy followed by endocrine therapy compared with using only the higher of the two Oncotype Dx estimated risks.Case Rep Oncol 2019;12:418 –420
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research